BioNTech is the Marketing Authorisation Holder for BNT162b2 (Original) and BNT162b2 Bivalent (Original/Omicron BA.4/BA.5) in the US, EU, UK, Canada, and other countries.
Pfizer and BioNTech have been among the leaders in the race to bring a combined COVID-19 and influenza vaccine to market, but have stumbled in the final straight. The companies reported mixed ...
German biotech firm BioNTech reported a loss of €665.3 million ($721 million) in 2024, as demand for its COVID-19 vaccines fell, according to the company's financial results report on Monday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback